PSMB10: Diagnosemarker und therapeutisches Target für chronische Abstoßung

PSMB10: A diagnosis marker and therapeutic target of chronic rejection.

PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique

Abstract

The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one reference expression level value for PSMB10 in at least one reference sample, and (c) diagnosing if said subject is or not undergoing chronic rejection of said grafted organ. The invention also concerns a diagnostic kit or microarray for performing the method of the invention. The invention further concerns the medical use of proteasome inhibitors for treating chronic rejection.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (20)

    Publication numberPublication dateAssigneeTitle
    WO-02084567-A2October 24, 2002Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National De La Recherche Scientifique (Cnrs)Method for analyzing t lymphocytes with the aid of t lymphocyte receptors of an organism
    WO-03033506-A1April 24, 2003Kyorin Pharmaceutical Co., Ltd., Nisshin Pharma Inc.Aminoborane acid derivative and proteasome inhibitory drug containing the same
    WO-03033507-A1April 24, 2003Kyorin Pharmaceutical Co., Ltd., Nisshin Pharma Inc.Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
    WO-03059898-A2July 24, 2003Eisai Co. Ltd.Analogues d'eponemycine et d'epoxomicine et leurs utilisations
    WO-2004014882-A2February 19, 2004Axys PharmaceuticalsProteasome inhibitors : peptide derivatives having c-terminal heteroaryl groups
    WO-2004064755-A2August 05, 2004Bristol-Myers Squibb CompanyMethods for inhibiting proteasome
    WO-2004071382-A2August 26, 2004Bayer Healthcare AgHeterocycles substitues
    WO-2005002572-A2January 13, 2005Nereus Pharmaceuticals, Inc.Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
    WO-2005016859-A2February 24, 2005Cephalon, Inc.Proteasome inhibitors and methods of using the same
    WO-2005021558-A2March 10, 2005Cephalon, Inc.Inhibiteurs de proteasomes et procedes d'utilisation de ceux-ci
    WO-2005070086-A2August 04, 2005The Board Of Trustees Of The Leland Stanford Junior University, Institut National De La Sante Et De La Recherche MedicaleProcedes et compositions pour la determination de phenotype a tolerance vis-a-vis du greffon chez un sujet
    WO-2005099687-A2October 27, 2005President And Fellows Of Harvard CollegeAnalogues de salinosporamide a
    WO-2006017842-A1February 16, 2006Proteolix, Inc.Composes pour l'inhibition enzymatique du proteasome
    WO-2006017981-A1February 23, 2006The Hong Kong Polytechnic University, Wayne State University, University Of South Florida, Mcgill UniversityDerives (-)-epigallocatechine gallates pour inhiber le proteasome
    WO-2006060809-A2June 08, 2006Nereus Pharmaceuticals, Inc.Methods of using [3.2.0] heterocyclic compounds and analogs thereof
    WO-2006086600-A1August 17, 2006Cephalon, Inc.Inhibiteurs du proteasome et leurs methodes d'utilisation
    WO-2006099261-A2September 21, 2006The University Of North Carolina At Chapel Hill, Mount Sinal School Of MedicineInhibiteurs puissants et spécifiques d'immunoprotéasomes
    WO-2006099421-A2September 21, 2006The Board Of Trustees Of The Leland Stanford Junior UniversityProcedes et compositions permettant d'evaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
    WO-2006131537-A2December 14, 2006Institut National De La Sante Et De La Recherche Medicale (Inserm)Procede permettant de diagnostiquer une tolerance a une greffe immune
    WO-9922729-A1May 14, 1999Centre De Recherche Du Centre Hospitalier De L'universite De MontrealUtilisation d'inhibiteurs de proteasomes dans le traitement du cancer, de l'inflammation, de maladies autoimmunes, du rejet du greffon et du choc septique

NO-Patent Citations (12)

    Title
    BROUARD S ET AL.: "Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation", AM. J. TRANSPLANT., vol. 5, no. 2, 2005, pages 330 - 340
    DONAUER J ET AL: "EXPRESSION PROFILING ON CHRONICALLY REJECTED TRANSPLANT KIDNEYS", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 76, no. 3, 15 August 2003 (2003-08-15), pages 539 - 547, XP009045200, ISSN: 0041-1337
    FLECHNER, S. M. ET AL., AM J TRANSPLANT, vol. 4, 2004, pages 1475 - 89
    GUEDAT P. ET AL., BMC BIOCHEM., vol. 8, no. 1, 22 November 2007 (2007-11-22), pages 14
    LOUIS S ET AL., CONTRASTING CD25HICD4+T CELLS/FOXP3 PATTERNS IN CHRONIC REJECTION AND OPERATIONAL DRUG-FREE TOLERANCE, vol. 81, no. 3, 2006, pages 398 - 407
    LUO H ET AL., TRANSPLANTATION, vol. 72, no. 2, 27 July 2001 (2001-07-27), pages 196 - 202
    MATEOS-MAZON JUAN ET AL: "Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation", HAEMATOLOGICA, FONDAZIONE FERRATA STORTI, ROME, IT, vol. 92, no. 9, 1 September 2007 (2007-09-01), pages 1295 - 1296, XP009108243, ISSN: 0390-6078
    MYUNG J ET AL., MED RES REV., vol. 21, no. 4, July 2001 (2001-07-01), pages 245 - 73
    PE APPLIED BIOSYSTEMS, vol. 2, 1997, pages 11 - 24
    SCHERER, A. ET AL., TRANSPLANTATION, vol. 75, 2003, pages 1323 - 30
    TODISCO E ET AL: "Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 48, no. 5, 1 May 2007 (2007-05-01), pages 1015 - 1018, XP009108241, ISSN: 1042-8194
    ZWEEGMAN S ET AL: "Immune-modulatory effects of bortezomib in GVHD", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 48, no. 5, 1 May 2007 (2007-05-01), pages 853 - 854, XP009108242, ISSN: 1042-8194

Cited By (1)

    Publication numberPublication dateAssigneeTitle
    US-8168803-B2May 01, 2012Nereus Pharmaceuticals, Inc.Methods of using [3.2.0] heterocyclic compounds and analogs thereof